HCV genotype 2 and 3 infections: what is the optimal duration for peginterferon alpha-2b and ribavirin therapy?

Affiliations

Comment

Andrew J Muir. Nat Clin Pract Gastroenterol Hepatol. 2005 Dec.

. 2005 Dec;2(12):568-9.

doi: 10.1038/ncpgasthep0337.

¹ Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27710, USA. muir0002@mc.duke.edu

No abstract available

Comment on

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.
Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A. Mangia A, et al. N Engl J Med. 2005 Jun 23;352(25):2609-17. doi: 10.1056/NEJMoa042608. N Engl J Med. 2005. PMID: 15972867 Clinical Trial.